Model: Requiring Rehabs to Offer Addiction Medication Would Cut Deaths

Requiring residential addiction treatment centers to offer buprenorphine or methadone to every patient who needs it would prevent overdose deaths and pay for itself in health gains, according to a simulation model of the Massachusetts treatment system published Monday in the journal Addiction. The same model found the policy could make things worse than the status quo if enough centers responded by closing rather than hiring prescribers.

The study, led by researchers at Boston Medical Center and the Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV and HIV, puts a population-level price on one of the oldest arguments in American addiction treatment: whether residential programs that advertise "drug-free" care should be allowed to operate as an entry point into the treatment system while refusing the medications that carry the strongest evidence for opioid use disorder.

Its authors frame the question as one of underuse. Medications for opioid use disorder are effective, they write, but underused in residential treatment centers — the residential end of the continuum being the setting most often chosen by families in a crisis and the one where prescribing capacity is thinnest.

What the model actually tested

The researchers built a cohort state-transition model of Massachusetts and compared four futures. In the first, the status quo, only a small fraction of residential centers offers medication. In the second, every center routinely offers it to admitted patients. The third adds a linkage step: patients discharged on medication are connected to outpatient treatment. The fourth extends that linkage to every patient leaving residential care, whether or not they were on medication during the stay.

Each strategy was run twice, once as a closed cohort that follows residential patients as individuals and once as an open cohort that estimates what happens across the state's whole population with opioid use disorder. Outcomes were measured in person-time on medication, overdose deaths, cost in 2024 dollars, quality-adjusted life-years and budget impact.

Five deaths prevented per 10,000, and a $40,195 price tag

In the closed cohort, making medication available at every residential center increased the time patients spent on buprenorphine or methadone by 36 percent and prevented about five overdose deaths per 10,000 people at one year, with an uncertainty range of one to six. Over a lifetime, that strategy added 0.0041 years of life per person at an incremental cost of $309.

Adding discharge linkage produced the better trade. The version that connects every departing patient to community treatment added 0.0096 life-years and 0.0080 quality-adjusted life-years while costing $198 less per person than the status quo — because the overdose deaths it prevented were expensive ones, and because a patient who stays on medication after discharge is a patient who is not cycling back through detox. The incremental cost-effectiveness ratio against the status quo came to $40,195 per quality-adjusted life-year gained, well below the $50,000 to $100,000 per QALY range that health economists typically cite as good value.

Translated to the state level, the preferred strategy prevented 2.64 overdose deaths per 10,000 people over ten years, a 0.40 percent reduction, and would add $9.65 million to Massachusetts health care spending over five years. That is a modest effect against the scale of the state's overdose toll, and the authors do not oversell it. Residential treatment is a short window in a long illness; the model's value comes from what happens at the door on the way out.

The scenario where the mandate backfires

The finding that matters most for anyone drafting legislation is buried in the sensitivity analysis. If centers refuse to offer medication and instead close — the study modeled a scenario in which 21 percent of sites shut down, reflecting programs whose philosophy rules out agonist treatment — outcomes end up worse than under the status quo. Patients who would have received residential care, counseling and a safe place to withdraw lose all of it, and the model does not have a place to put them.

That risk is not hypothetical in the current market. Residential and detox programs have been closing or shedding beds as reimbursement lags costs, including a Portland program that closed 20 maternal treatment beds and a Maine detox unit that shut down over MaineCare rates. A mandate that arrives without a funding stream is a mandate that some operators will answer with a closure notice. The policy question the model raises is therefore not whether medication belongs in residential care — the evidence for that is not in serious dispute — but whether a state can write the requirement in a way that pays for the prescriber and the care navigation rather than simply ordering them into existence.

Why residential care is the test case

Residential and detox settings are where a large share of treatment episodes begin, and the handoff between that setting and ongoing medication is where continuity is most easily lost. The model's linkage arm is a formal version of what clinicians describe informally: the discharge plan is the treatment. A patient who leaves a 28-day program with a phone number and no appointment is, statistically, back in the same risk pool that brought them in.

The Massachusetts result also lands at a moment when methadone capacity is expanding unevenly. New York added 43 methadone programs in five years, a 44 percent increase, as reported here on Monday, while many states have added few or none. Residential centers sit upstream of that capacity: they are the setting where a patient's first impression of medication is formed, and where a counselor's skepticism about buprenorphine can become a patient's reluctance to try it.

The study is a simulation, not a trial. It cannot prove that a real mandate in a real state would produce a 36 percent increase in medication use, and its cost estimates depend on assumptions about Massachusetts prices and practice that will not hold everywhere. What it can do is put a number on the alternative that states currently accept by default. People looking for care that includes medication can start with the medication-assisted treatment overview, buprenorphine and methadone pages, or search opioid treatment programs and residential and outpatient levels of care by state.